Durvalumab: First Global Approval

Syed, Yahiya Y.

doi:10.1007/s40265-017-0782-5

Cited by 131 publications

(97 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Oncologist 2020;25: [94][95][96][97][98] Immunotherapy in the form of checkpoint blockade has resulted in impressive responses for several previously refractory tumor types. Indeed, the U.S. Food and Drug Administration (FDA) has now approved seven checkpoint inhibitors: pembrolizumab, nivolumab, durvalumab, avelumab, atezolizumab, cemiplimab, and ipilimumab [1][2][3][4][5][6][7]. Immune checkpoint inhibitors mediate responses by reactivating the immune system.…”

mentioning

confidence: 99%

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

et al. 2019

View full text Add to dashboard Cite

There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various cancers. These drugs are associated with profound, durable responses in a subset of patients with advanced cancers. Unfortunately, in addition to individuals whose tumors show resistance, there is a minority subgroup treated with ICIs who demonstrate a paradoxical acceleration in the rate of growth or their tumors-hyperprogressive disease. Hyperprogressive disease is associated with significantly worse outcomes in these patients. This phenomenon, though still a matter of dispute, has been recognized by multiple groups of investigators across the globe and in diverse types of cancers.Correspondence: Razelle Kurzrock, M.D.

show abstract

mentioning

confidence: 99%

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…To date, six monoclonal antibodies targeting the PD-1/PD-L1 pathway have been approved by the US FDA for clinical use; among such antibodies, pembrolizumab, nivolumab, and cemiplimab are anti-PD-1 antibodies [209,210], whereas durvalumab, atezolizumab, and avelumab are anti-PD-L1 antibodies [211]. Tumeh et al [212] analyzed samples from patients with melanoma in the phase I clinical trials of pembrolizumab and found that the CD8 T cell density at the tumor site was significantly lower in patients who did not respond to pembrolizumab compared with that of patients who responded to pembrolizumab.…”

Section: Combinations Of Ovs and Pd-1/pd-l1 Blockadementioning

confidence: 99%

Development of oncolytic virotherapy: from genetic modification to combination therapy

et al. 2020

View full text Add to dashboard Cite

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

show abstract

“…Durvalumab (MEDI4736) is a human IgG1 κ monoclonal antibody against PD‐L1. It blocks the interaction of PD‐L1 with PD‐1 and CD80 molecules . Based on DANUBE (NCT02516241), BISCAY (NCT02546661), and study 10 (NCT02261220) results, FDA, on 1 May 2017, granted approval to durvalumab as second‐line therapy for patients with locally advanced or metastatic bladder cancer whom prognosis is poor …”

Section: Immune Checkpoint Inhibitor (Ici) For Treatment Of Bladder Cmentioning

confidence: 99%

Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy

Moghadam

Nowroozi

2019

Scand J Immunol

View full text Add to dashboard Cite

Bladder cancer is one of the leading causes of death worldwide. The main immune mechanisms which lead to bladder cancer development or treatment outcomes have yet to be elucidated. Toll‐like receptors (TLRs) play key roles against cancer. TLRs are expressed both on immune cells and on tumour cells and drive immune responses in progression as well as treatment of cancer. Identification of signalling pathways via TLRs could revolutionize further improvement of therapeutic strategies against cancers in the future. According to the recent studies, TLRs agonists are effective immunostimulants and have important role in induction of immune responses with immunotherapeutic potential against several diseases including cancer. They play an important role in the bladder urothelium as a part of immune defence against uropathogens. On the other hand, decreased TLRs expression was found in bladder tumours, particularly in non‐muscle‐invasive ones. Bacillus Calmette‐Guerin (BCG) (agonist of TLR2 and TLR4) is approved by US FDA for immunotherapy of bladder cancer. Despite high efficiency, immunotherapy with BCG may cause toxicity and adverse effects. Nowadays, in vitro and in vivo studies have been conducted to find alternative options for non‐responder patients. Studies on TLR agonists for bladder cancer treatment have shown promising results. In this review, we discuss recent data about mechanisms played by TLRs in bladder cancer developments as well as therapeutic application of TLR agonists in cancer treatment.

show abstract

Durvalumab: First Global Approval

Cited by 131 publications

References 22 publications

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Development of oncolytic virotherapy: from genetic modification to combination therapy

Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy

Contact Info

Product

Resources

About